Computed tomographic airway morphology after targeted lung denervation treatment in COPD

AIRFLOW-2 Study Group; Jorine E. Hartman; Felix Herth; Pallav Shah; Christophe Pison; Arschang Valipour; Dirk Jan Slebos

doi:10.1016/j.rmed.2022.107059

Computed tomographic airway morphology after targeted lung denervation treatment in COPD

AIRFLOW-2 Study Group, Jorine E. Hartman^*, Felix Herth, Pallav Shah, Christophe Pison, Arschang Valipour, Dirk Jan Slebos

^*Corresponding author for this work

Groningen Research Institute for Asthma and COPD (GRIAC)

Research output: Contribution to journal › Letter › Academic › peer-review

3 Citations (Scopus)

78 Downloads (Pure)

Abstract

This post-hoc analysis of the AIRFLOW-2 trial investigated the changes in airway CT-parameters after targeted lung denervation (TLD) and whether these changes are associated with treatment response. In the treatment group (n = 32), an improvement in air trapping was significantly associated with an improvement in residual volume (RV). Furthermore, improvements in Pi10 and airway lumen were significantly associated with an improvement in both RV and FEV₁. Our results could suggest that when improving airway characteristics like decreasing airway wall thickness and increasing the airway lumen, this leads to less air trapping and an improvement in clinical outcomes.

Original language	English
Article number	107059
Number of pages	4
Journal	Respiratory Medicine
Volume	206
DOIs	https://doi.org/10.1016/j.rmed.2022.107059
Publication status	Published - Jan-2023

Access to Document

10.1016/j.rmed.2022.107059Licence: CC BY

Computed tomographic airway morphology after targeted lung denervation treatment in COPDFinal publisher's version, 1.88 MBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{3e7ee116498346a9834dfc3ffb07dd1b,

title = "Computed tomographic airway morphology after targeted lung denervation treatment in COPD",

abstract = "This post-hoc analysis of the AIRFLOW-2 trial investigated the changes in airway CT-parameters after targeted lung denervation (TLD) and whether these changes are associated with treatment response. In the treatment group (n = 32), an improvement in air trapping was significantly associated with an improvement in residual volume (RV). Furthermore, improvements in Pi10 and airway lumen were significantly associated with an improvement in both RV and FEV1. Our results could suggest that when improving airway characteristics like decreasing airway wall thickness and increasing the airway lumen, this leads to less air trapping and an improvement in clinical outcomes.",

author = "{AIRFLOW-2 Study Group} and Hartman, {Jorine E.} and Felix Herth and Pallav Shah and Christophe Pison and Arschang Valipour and Slebos, {Dirk Jan} and Christine Abele and Irene Firlinger and Kiran Kothakuzhakal and Marina Duller and Bernd Lamprecht and Roland Kropfmueller and Kornelia Holzmann and Sandra Rathmeier and Ralf Hubner and Leonore Erdmann and Bettina Temmesfeld-Wollbr{\"u}ck and {Ruwwe Gl{\"o}senkamp}, Christoph and Wolfgang Gesierich and Frank Reichenberger and Christa Niehaus and Felix Herth and Ralf Eberhardt and Daniela Gompelmann and Brigitte Rump and Kaid Darwiche and Stephan Eisenmann and Ulrike Kaiser and Birte Schwarz and Ulrike Sampel and Christian Schumann and Robert Kaiser and Kathryn Schumann-Stoiber and Dirk Skowasch and Sabine Ring and Amandine Briault and Francois Arbib and Marie Jondot and Thierry Perez and Clement Fournier and Regis Matran and Michele Catto and Nathalie Bautin and {De Broucker}, Virginie and Marie Willemin and Anne Prevotat and Ludivine Wemeau and Alice Gicquello and Morgane Foulon and Hartman, {Jorine E.}",

note = "Funding Information: The AIRFLOW-2 trial was funded by Nuvaira Inc, Minneapolis, MN, USA . The funding source had no involvement in this analysis or in the writing of this manuscript. Funding Information: The AIRFLOW-2 trial was funded by Nuvaira Inc, Minneapolis, MN, USA. The funding source had no involvement in this analysis or in the writing of this manuscript.We would like to thank the Dutch Foundation for Asthma Prevention (Noorderlijke CARA stichting) for the grant we received which allowed us to purchase the software used for this analysis. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2023",

month = jan,

doi = "10.1016/j.rmed.2022.107059",

language = "English",

volume = "206",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "W B SAUNDERS CO LTD",

}

TY - JOUR

T1 - Computed tomographic airway morphology after targeted lung denervation treatment in COPD

AU - AIRFLOW-2 Study Group

AU - Hartman, Jorine E.

AU - Herth, Felix

AU - Shah, Pallav

AU - Pison, Christophe

AU - Valipour, Arschang

AU - Slebos, Dirk Jan

AU - Abele, Christine

AU - Firlinger, Irene

AU - Kothakuzhakal, Kiran

AU - Duller, Marina

AU - Lamprecht, Bernd

AU - Kropfmueller, Roland

AU - Holzmann, Kornelia

AU - Rathmeier, Sandra

AU - Hubner, Ralf

AU - Erdmann, Leonore

AU - Temmesfeld-Wollbrück, Bettina

AU - Ruwwe Glösenkamp, Christoph

AU - Gesierich, Wolfgang

AU - Reichenberger, Frank

AU - Niehaus, Christa

AU - Herth, Felix

AU - Eberhardt, Ralf

AU - Gompelmann, Daniela

AU - Rump, Brigitte

AU - Darwiche, Kaid

AU - Eisenmann, Stephan

AU - Kaiser, Ulrike

AU - Schwarz, Birte

AU - Sampel, Ulrike

AU - Schumann, Christian

AU - Kaiser, Robert

AU - Schumann-Stoiber, Kathryn

AU - Skowasch, Dirk

AU - Ring, Sabine

AU - Briault, Amandine

AU - Arbib, Francois

AU - Jondot, Marie

AU - Perez, Thierry

AU - Fournier, Clement

AU - Matran, Regis

AU - Catto, Michele

AU - Bautin, Nathalie

AU - De Broucker, Virginie

AU - Willemin, Marie

AU - Prevotat, Anne

AU - Wemeau, Ludivine

AU - Gicquello, Alice

AU - Foulon, Morgane

AU - Hartman, Jorine E.

N1 - Funding Information: The AIRFLOW-2 trial was funded by Nuvaira Inc, Minneapolis, MN, USA . The funding source had no involvement in this analysis or in the writing of this manuscript. Funding Information: The AIRFLOW-2 trial was funded by Nuvaira Inc, Minneapolis, MN, USA. The funding source had no involvement in this analysis or in the writing of this manuscript.We would like to thank the Dutch Foundation for Asthma Prevention (Noorderlijke CARA stichting) for the grant we received which allowed us to purchase the software used for this analysis. Publisher Copyright: © 2022 The Author(s)

PY - 2023/1

Y1 - 2023/1

N2 - This post-hoc analysis of the AIRFLOW-2 trial investigated the changes in airway CT-parameters after targeted lung denervation (TLD) and whether these changes are associated with treatment response. In the treatment group (n = 32), an improvement in air trapping was significantly associated with an improvement in residual volume (RV). Furthermore, improvements in Pi10 and airway lumen were significantly associated with an improvement in both RV and FEV1. Our results could suggest that when improving airway characteristics like decreasing airway wall thickness and increasing the airway lumen, this leads to less air trapping and an improvement in clinical outcomes.

AB - This post-hoc analysis of the AIRFLOW-2 trial investigated the changes in airway CT-parameters after targeted lung denervation (TLD) and whether these changes are associated with treatment response. In the treatment group (n = 32), an improvement in air trapping was significantly associated with an improvement in residual volume (RV). Furthermore, improvements in Pi10 and airway lumen were significantly associated with an improvement in both RV and FEV1. Our results could suggest that when improving airway characteristics like decreasing airway wall thickness and increasing the airway lumen, this leads to less air trapping and an improvement in clinical outcomes.

U2 - 10.1016/j.rmed.2022.107059

DO - 10.1016/j.rmed.2022.107059

M3 - Letter

C2 - 36459953

AN - SCOPUS:85142827916

SN - 0954-6111

VL - 206

JO - Respiratory Medicine

JF - Respiratory Medicine

M1 - 107059

ER -

Computed tomographic airway morphology after targeted lung denervation treatment in COPD

Abstract

Access to Document

Handle.net

Fingerprint

Cite this